Using Sodium Bicarbonate Ringer's Solution in Liver Surgery

The Application of Sodium Bicarbonate Ringer's Solution on Perioperative Lactic Acid Concentration and Early Recovery Quality in Patients Undergoing Laparoscopic Hepatectomy

This study is testing if using sodium bicarbonate Ringer's solution during liver surgery helps patients stay stable compared to the usual lactate Ringer's solution.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 100 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: The First Affiliated Hospital with Nanjing Medical University (other)
• Locations: 1 site (Nanjing, Jiangsu)
• Trial ID: NCT05830136 on ClinicalTrials.gov

What this trial studies

This study compares the effects of sodium bicarbonate Ringer's solution and lactate Ringer's solution on patients undergoing laparoscopic liver resection. It is a single-center, prospective randomized controlled trial involving 100 patients, who are divided into two groups to assess various hemodynamic and biochemical parameters at different stages of the surgery. The goal is to evaluate the potential advantages of sodium bicarbonate Ringer's solution in maintaining internal balance during the procedure.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older who are scheduled for laparoscopic hepatectomy and can provide informed consent.

Not a fit: Patients under 18, pregnant women, and those with significant cardiac, pulmonary, or renal conditions may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could improve patient outcomes during laparoscopic liver surgery by optimizing hemodynamic stability.

How similar studies have performed: While the specific application of sodium bicarbonate Ringer's solution in this context may be novel, similar studies have shown promising results with alternative solutions in surgical settings.

Eligibility criteria

Inclusion Criteria:

1. ≥18 years old,
2. patients who plan to undergoing laparoscopic hepatectomy ;
3. Willing to sign informed consent.

Exclusion Criteria:

1. age \<18 years
2. pregnancy
3. active cardiac conditions (unstable coronary syndromes, decompensated heart failure, significant arrhythmias, severe valvular disease, history of congestive heart failure)
4. history of significant cerebrovascular disease
5. restrictive or obstructive pulmonary disease
6. uncontrolled hypertension
7. renal dysfunction (glomerular filtration rate \<60 mL/min),
8. evidence of hepatic metabolic disorder (bilirubin \>35 mmol/L)
9. presence of active infection

Where this trial is running

Nanjing, Jiangsu

• Shijiang Liu — Nanjing, Jiangsu, China (RECRUITING)

Study contacts

• Principal investigator: Shijiang Liu — The First Affiliated Hospital with Nanjing Medical University
• Study coordinator: Shijiang Liu

Conditions: Hepatic Ischemia